Geographical and temporal variations in clozapine prescription for schizophrenia

Jimmi Nielsen; Rasmus Røge; Ole Schjerning; Holger J Sørensen; David Taylor

doi:10.1016/j.euroneuro.2012.03.003

Geographical and temporal variations in clozapine prescription for schizophrenia

Jimmi Nielsen
, Rasmus Røge
, Ole Schjerning
, Holger J Sørensen
, David Taylor

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Despite its unsurpassed efficacy in treatment-resistant schizophrenia, clozapine remains underutilized. Trends in the prescription of clozapine in patients with ICD-10 F20.x schizophrenia were assessed using data from Danish national registers. Three substudies were carried out: (i) an assessment of differences in national prescription patterns between 1996 and 2007 using a cross-sectional design; (ii) a comparison of time from first schizophrenia diagnosis to first prescription of clozapine in a five-year cohort study, using the Cox regression model, of two patient groups who were first diagnosed in 1996 and in 2003; (iii) an assessment of differences in the general psychiatric hospitals' use of clozapine in 2009. The results are as follows: (i) The percentage of schizophrenia patients receiving clozapine rose from 9.0% in 1996 to 10.1% in 2007 (p

Original language	English
Journal	European Neuropsychopharmacology
Volume	22
Issue number	11
Pages (from-to)	818-24
Number of pages	7
ISSN	0924-977X
DOIs	https://doi.org/10.1016/j.euroneuro.2012.03.003
Publication status	Published - 2012

Access to Document

10.1016/j.euroneuro.2012.03.003

Library access?

Check availability at the Royal Danish Library

Cite this

@article{df33405c6e0e4f62b98cd25b559abb3d,

title = "Geographical and temporal variations in clozapine prescription for schizophrenia",

abstract = "Despite its unsurpassed efficacy in treatment-resistant schizophrenia, clozapine remains underutilized. Trends in the prescription of clozapine in patients with ICD-10 F20.x schizophrenia were assessed using data from Danish national registers. Three substudies were carried out: (i) an assessment of differences in national prescription patterns between 1996 and 2007 using a cross-sectional design; (ii) a comparison of time from first schizophrenia diagnosis to first prescription of clozapine in a five-year cohort study, using the Cox regression model, of two patient groups who were first diagnosed in 1996 and in 2003; (iii) an assessment of differences in the general psychiatric hospitals' use of clozapine in 2009. The results are as follows: (i) The percentage of schizophrenia patients receiving clozapine rose from 9.0\% in 1996 to 10.1\% in 2007 (p",

author = "Jimmi Nielsen and Rasmus R{\o}ge and Ole Schjerning and S{\o}rensen, \{Holger J\} and David Taylor",

year = "2012",

doi = "10.1016/j.euroneuro.2012.03.003",

language = "English",

volume = "22",

pages = "818--24",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - Geographical and temporal variations in clozapine prescription for schizophrenia

AU - Nielsen, Jimmi

AU - Røge, Rasmus

AU - Schjerning, Ole

AU - Sørensen, Holger J

AU - Taylor, David

PY - 2012

Y1 - 2012

N2 - Despite its unsurpassed efficacy in treatment-resistant schizophrenia, clozapine remains underutilized. Trends in the prescription of clozapine in patients with ICD-10 F20.x schizophrenia were assessed using data from Danish national registers. Three substudies were carried out: (i) an assessment of differences in national prescription patterns between 1996 and 2007 using a cross-sectional design; (ii) a comparison of time from first schizophrenia diagnosis to first prescription of clozapine in a five-year cohort study, using the Cox regression model, of two patient groups who were first diagnosed in 1996 and in 2003; (iii) an assessment of differences in the general psychiatric hospitals' use of clozapine in 2009. The results are as follows: (i) The percentage of schizophrenia patients receiving clozapine rose from 9.0% in 1996 to 10.1% in 2007 (p

AB - Despite its unsurpassed efficacy in treatment-resistant schizophrenia, clozapine remains underutilized. Trends in the prescription of clozapine in patients with ICD-10 F20.x schizophrenia were assessed using data from Danish national registers. Three substudies were carried out: (i) an assessment of differences in national prescription patterns between 1996 and 2007 using a cross-sectional design; (ii) a comparison of time from first schizophrenia diagnosis to first prescription of clozapine in a five-year cohort study, using the Cox regression model, of two patient groups who were first diagnosed in 1996 and in 2003; (iii) an assessment of differences in the general psychiatric hospitals' use of clozapine in 2009. The results are as follows: (i) The percentage of schizophrenia patients receiving clozapine rose from 9.0% in 1996 to 10.1% in 2007 (p

U2 - 10.1016/j.euroneuro.2012.03.003

DO - 10.1016/j.euroneuro.2012.03.003

M3 - Journal article

C2 - 22503785

SN - 0924-977X

VL - 22

SP - 818

EP - 824

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

IS - 11

ER -